The hypothesis was that tumor node (TN) category of disease has a meaningful impact on survival (diseasefree survival [DSF] and overall survival [OS]), colostomy failure (CF), and relapse (local-regional failure [LRF] and distant metastases [DM]) in patients with anal cancer treated with concurrent chemoradiation. Six TN categories were compared (T2N0, T3N0, T4N0, T2N1-3, T3N1-3, and T4N1-3). All endpoints Purpose: The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin. The intent of the current analysis was to determine the impact of tumor node (TN) category of disease on survival (DFS and OS), colostomy failure (CF), and relapse (local-regional failure [LRF] and distant metastases [DM]) in this patient group. Methods and Materials: DFS and OS were estimated univariately by using the Kaplan-Meier method, and 6 TN categories were compared by the logerank test (T2N0, T3N0, T4N0, T2N1-3, T3N1-3, and T4N1-3). Time to relapse and colostomy were estimated by the cumulative incidence method, and TN categories were compared using Gray's test. Results: Of 682 patients, 620 were analyzable for outcomes by TN category. All endpoints showed statistically significant differences among the TN categories of disease (OS, P<.0001; DFS, P<.0001; LRF, P<.0001; DM, PZ.0011; CF, PZ.01). Patients with the poorest OS, DFS, and LRF outcomes were those with T3-4N-positive (þ) disease. CF was lowest for T2N0 and T2Nþ (11%, 11%, respectively) and worst for the T4N0, T3Nþ, and T4Nþ categories (26%, 27%, 24%, respectively). Conclusions: TN category of disease has a statistically significant impact on OS, DFS, LRF, DM, and CF in patients treated with CCRT and provides excellent prognostic information for
Introduction
Phase 2 (1-3) and subsequent randomized phase 3 trials (4-10) have established concurrent chemoradiation (CCRT) as the initial treatment of choice for most patients with anal carcinoma. CCRT achieves sphincter preservation in many patients, allowing surgical resection to be kept in reserve as a salvage maneuver (11) . A phase 3 trial by the Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group (RTOG 87-04/ECOG 1289) ECOG 1289) demonstrated that RT plus concurrent infusion with fluorouracil (5-FU) plus mitomycin (MMC) both improved local control and had a lower colostomy rate than RT plus 5-FU (4). Phase 3 trials from the United Kingdom Coordinating Committee on Cancer Research and the European Organization for the Research and Treatment of Cancer (EORTC) established that CCRT with 5-FU/MMC was superior to RT alone with regard to local control and colostomy failure (CF) but had no overall survival (OS) advantage (5, 6) .
In an attempt to determine whether concurrent MMC during RT plus 5-FU infusion could be replaced with cisplatin (CDDP), a US GI Intergroup phase 3 trial coordinated by RTOG (RTOG 98-11) was initiated to test RT plus concurrent 5-FU/MMC therapy versus induction 5-FU/CDDP therapy followed by RT plus concurrent 5-FU/CDDP (7) . Disease-free survival (DFS) was the primary endpoint, and secondary endpoints were OS, CF, and disease relapse. An initial analysis of RTOG 98-11 showed a decrease in CF for RT plus 5-FU/MMC versus RT plus 5-FU/ CDDP, with 5-year rates of 10% versus 19% (PZ.02), respectively, but no impact on either DFS or OS (7) . On the basis of a long-term updated analysis, therapy with RT plus 5-FU/MMC had statistically better DFS and OS rates than RT plus 5-FU/ CDDP (5-year DFS: 67.8% vs 57.8%, respectively, PZ.006; 5-year OS: 78.3% vs 70.7%, respectively, PZ.026) (8) .
Secondary analyses of RTOG 98-11 were previously performed to evaluate OS, DFS, and time to colostomy by using various prognostic factors (9, 10) . In an analysis of predictors for colostomy, only tumor diameter >5 cm predicted for time to colostomy (PZ.008). In an analysis that evaluated prognostic factors for survival (10) , patients with >5-cm node-positive (Nþ) tumors had the worst DFS and OS rates, and those with 5 cm N0 tumors had the best DFS and OS (10) .
The prognosis for patients with T2-4N0 or T2-4Nþ disease could not, however, be derived from prior RTOG 98-11 reports. According to American Joint Committee on Cancer definition (fifth edition), T4 tumor category is a tumor of any size that invades adjacent organs. Therefore, the size category of >2 to 5 cm included patients with both T2 (tumors >2 cm but 5 cm, greatest dimension) and T4 lesions, and the >5-cm size category included patients with both T3 (tumors >5 cm, greatest dimension) and T4 lesions. Accordingly, it was felt that a further analysis of RTOG 98-11 was needed to determine the impact of pretreatment TN category of disease on survival, disease relapse, and CF.
Methods and Materials
Infrastructure, hypothesis, and objectives RTOG 98-11 was a US GI Intergroup trial coordinated by RTOG, with participation by ECOG, Cancer and Leukemia Group B, North Central Cancer Treatment Group, Southwest Oncology Group, and RTOG. The primary objective of the study was to observe an increase in 5-year DFS from 63% with RT plus concurrent 5-FU/MMC therapy to 73% with RT plus concurrent 5-FU/CDDP. Secondary objectives included OS, LRF, CF, and differences in toxicities.
The objective of the current analysis (January 25, 2012) was to determine the impact of each TN category of disease on survival (OS, DFS), disease relapse (local-regional [LRF], distant [DM] ) and CF in the RTOG 98-11 phase 3 trial.
Patient eligibility
Patients with histologically documented squamous, basaloid, or cloacogenic carcinoma of the anal canal were eligible, provided they were 18 years of age or older and had Karnofsky performance status 60, T2-4 category cancer with any N category (pelvic or inguinal), and adequate organ function, and were willing to provide written consent. Patients were excluded if they had T1N0-3 or M1 cancer, severe comorbid conditions (including acquired immunodeficiency syndrome), or major malignancy, unless successfully treated and disease-free for at least 5 years.
Evaluations
Before treatment, patients underwent baseline proctoscopy or sigmoidoscopy, chest radiography, and computerized tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis to establish the stage of disease, plus blood and serum chemistry evaluations to determine the adequacy of hepatic, renal, and bone marrow function. After treatment, patients were re-evaluated similar to baseline and were then followed every 3 months for 2 years, every 6 months for 1 year, and then yearly.
Randomization, stratification, and treatment
Patients were randomized to receive RT plus concurrent infusion of 5-FU/MMC (Arm A; control arm) or induction 5-FU/CDDP therapy followed by RT plus concurrent 5-FU/CDDP therapy (Arm B). Patients were stratified according to gender, clinical node status (N0 vs Nþ), and size of primary (>2-5 cm or >5 cm).
Details of both RT and the chemotherapy components of treatment are described in depth in the initial publication (7) . All patients were to receive a minimum dose of 45 Gy in 25 fractions of 1.8 Gy over 5 weeks to the primary cancer with megavoltage radiation, using anteroposterior-posteroanterior or multifield techniques. Noninvolved nodal sites at risk received 30.6 to 36 Gy in 17 to 20 fractions of 1.8 Gy over 3.5 to 4 weeks. For patients with T3, T4, or Nþ disease or T2 patients with residual disease after 45 Gy, the intent was to deliver an additional boost of 10 to 14 Gy in 2-Gy fractions to the primary tumor and involved nodal disease (total dose of 55-59 Gy in 30-32 fractions over 5.5-6.5 weeks).
Statistical methods
DFS and OS were univariately estimated by using the KaplanMeier method (12) , and 6 TN categories were compared using the logerank test (T2N0, T3N0, T4N0, T2Nþ, T3Nþ, T4T4NþNþ) (13) . LRF, DM, and CF were estimated by using the cumulative incidence method (14) , and results by TN category were compared using Gray's test (15) . Initial analyses of OS, DFS, and LRF led to collapsing TN categories into 2 TN groups (T2-3N0 vs T4N0/Any TNþ) and 3 TN groups (T2-3N0, T4N0/T2Nþ, T3-4Nþ) for further analyses.
Univariate and multivariate Cox proportional hazards models (16) were used to determine whether there was any correlation between the TN categories of disease with regard to OS, DFS, LRF, DM, and CF. Models looking at the 6 TN categories are coded with the reference level of T2N0. A hazard ratio (HR) >1 indicated an increased risk of failure for the other TN categories relative to T2N0. For comparison of the 2 TN groupings, we used a reference level of T2-3N0. When comparing the 3 TN groupings, the reference level was T4N0/T2Nþ (HR >1 for T2-3N0 or T3-4Nþ categories indicated increased risk of failure relative to T4N0/ T2Nþ; HR <1 for T2-3N0 or T3-4Nþ categories indicated a decreased risk of failure relative to T4N0/T2Nþ).
Results

Patient characteristics
Of 682 patients randomized to the trial, 649 were evaluable for the initial analysis (25 were ineligible, 6 withdrew consent, 2 had no follow-up information). Of the 649 patients, 620 were evaluable for the current analysis; an additional 29 were excluded because of uncertain nodal status.
Survival and relapse by TN category of disease
In the 620 evaluable patients, all endpoints showed statistically significant differences among the TN categories of disease, as seen in Table 1 and Figures 1 and 2 (OS, P<.0001; DFS, P<.0001; LRF, P<.0001; DM, PZ.0011; CF, PZ.01). OS, LRF, DM, and CF were not statistically different for T2N0 and T3N0 patients but were statistically worse for the other TN categories. For DFS, all TN categories were statistically worse than T2N0.
The best OS and DFS rates and LRF 5-year outcomes were seen in patients with T2N0 and T3N0 categories of disease (OS, 82% and 74%, respectively; DFS, 72% and 61%, respectively; LRF, 17% and 18%, respectively) and the worst outcomes in Six TN groups  T2N0  323  76  82  110  72  57  17  38  10  36  11  T3N0  96  30  74  45  61  17  18  13  14  15  13  T4N0  31  14  57  16  50  11  37  7  21  8  26  T2N1-3  99  38  70  50  57  26  26  28  27  11  11  T3N1-3  46  20  57  29  38  20  44  11  24  12  27  T4N1-3  25  16  42  18  31  15 patients with T4N0, T3N1-3, and T4N1-3 disease (OS, 57%, 57%, and 42%, respectively; DFS, 50%, 38%, and 31%, respectively; LRF, 37%, 44%, and 60%, respectively). Survival and LRF 5-year outcomes for T2Nþ category (OS, 70%; DFS, 57%; LRF, 26%) were intermediate between T3N0 and T4N0 disease.
Outcomes by TN category groups
The impact of TN category group on survival, relapse, and CF is seen in Table 1 . When separated into 2 TN groups (T2-3N0 vs T4N0/T2-4Nþ), patients with T2-3N0 disease had statistically better outcomes for 5-year OS (80% vs 62%, respectively, P<.0001); DFS (70% vs 49%, respectively, P<.0001), LRF (17% vs 36%, respectively, P<.0001), and DM (11% vs 25%, respectively, P<.0001). When separated into 3 TN groups (T2-3N0, T4N0/T2Nþ, and T3-4Nþ), patients with T2-3N0 disease had better survival and relapse outcomes than patients in the other 2 TN groups with regard to 5-year OS (80% vs 67% and 52%, respectively, P<.0001), DFS (70% vs 56% and 36%, respectively, P<.0001), LRF (17% vs 28% and 50%, respectively, P<.0001), and DM (11% vs 26% and 24%, respectively, P<.0001). Patients with T4N0/T2Nþ lesions had intermediate outcomes relative to the other 2 groups (Table 1 and see Supplementary Table 1b) .
Colostomy failure by TN category and treatment
Colostomy failure was lowest in patients with T2N0 and T2Nþ lesions (3-year: 11%, 11%, respectively) and highest in patients with T4N0, T3Nþ, and T4Nþ lesions (3-year: 26%, 27%, and 24%, respectively) ( Table 1 ). The differences in CF by TN category did not achieve statistical significance in the RT plus 5-FU/CDDP treatment arm (PZ.11) ( Table 2 ). There was a trend toward a statistically significant difference in CF among the 6 TN categories of disease in the RT plus 5-FU/MMC arm (PZ.066); T2N0 and T2Nþ patients still had the lowest rates of CF (3-year: 9%, 4%, respectively). Only the T4Nþ group, however, had statistically significantly worse CF than the T2N0 group.
Survival and relapse by TN category and treatment
When treatment arms were analyzed separately (Tables 3 and 4) 
Summary
For all the results in this analysis, it is important to note that sample sizes for some TN categories were very small, resulting in wide confidence intervals, and that RTOG 98-11 was not designed nor powered for this type of subset analysis. There may be differences among TN categories for some endpoints that were unable to be detected statistically due to inadequate power.
Discussion
For several decades, CCRT has been the preferred initial treatment in most anal carcinoma patients because of a high probability of sphincter preservation (1-10). While differences in DFS and local control had been noted in phase 3 trials, this had not translated 
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into improvements in OS, as surgical salvage was feasible with abdominoperineal resection (11) .
In the initial analysis of RTOG 98-11, there was a statistically significant decrease in CF for RT plus 5-FU/MMC therapy compared to RT plus 5-FU/CDDP, with 5-year CF rates of 10% versus 19%, respectively (PZ.02), but no impact on either DFS or OS (7) . On the basis of the long-term updated analysis, RT plus 5-FU/MMC had statistically better DFS and OS rates than RT plus 5-FU/CDDP (5-year DFS: 67.8% vs 57.8%, respectively, PZ.006; 5-year OS: 78.3% vs 70.7%, respectively, PZ.026) (8).
Outcomes by tumor size and T category of disease
Tumor size appears to have a moderate impact on outcomes when anal cancer is treated with CCRT. In the RTOG 8704/ECOG 1289 Abbreviations: CDDP Z cisplatin; CIZ confidence interval; HR Z hazard ratio; MMC, mitomycin; TF Z total failures. * Some 3-year estimates might be unstable due to small sample sizes and, therefore, too few patients at risk at 3 years.
y P value from c 2 test using the Cox proportional HR model. z P value from the Gray's test.
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Anal CA: TN impact on survival, relapse phase 3 study, positive biopsy samples were found 6 weeks after completion of CCRT in 17% versus 7% of patients with primary tumors 5 cm versus <5 cm in diameter, respectively (PZ.02) (4). Differences in local control have also been reported based on maximum tumor diameter. In RTOG 8314, 3-year local control (LC) was 84% versus 62% in patients with tumors <3 cm versus those with tumors 3 cm (2). In a Princess Margaret Hospital (PMH) CCRT series, LC was 94% versus 72% for patients with 2 cm versus those with >2 cm tumors (3) . No differences in LC were found in the PMH series for patients with tumors of 2 to 5 cm versus those with >5 cm, unless there was tumor invasion of adjacent structures (T4 category), in whom LC was 62%. However, anal function was maintained in w67% of PMH T4 patients (3). Secondary analyses of US GI Intergroup RTOG 98-11 were previously performed to evaluate outcomes by various prognostic factors; the first analysis attempted to find a pretreatment variable that predicted for colostomy (9) . Only tumor diameter >5 cm predicted for time to colostomy (PZ.008).
Outcomes by N category of disease
Nodal involvement at time of diagnosis was associated with worse prognosis in most series. In the EORTC phase 3 trial, patients with involved nodes had inferior LC and OS independent of extent of nodal involvement (6) . In the PMH series, 5-year cause-specific survival for clinically node-positive versus node-negative patients was 57% versus 81%, respectively (PZ.07) (3).
In the initial RTOG 9811 secondary analysis of prognostic factors, 5-year DFS was 64% for node-negative patients versus 35% for node-positive patients (logerank, P<.0001) (9). The 5-year OS rates favored node-negative patients at 80% versus 57% (logerank P<.0001).
Outcomes by TN category: RTOG 98-11 analyses
In an RTOG 98-11 analysis that attempted to confirm or find new prognostic factors for survival (10) , combinations of tumor size (>2-5 cm vs >5 cm) and clinically involved nodes (N0, Nþ) were analyzed (10) . Patients with >5 cm tumor and Nþ had the worst DFS and OS rates, and those with 5 cm N0 tumors had the best DFS and OS rates (3-year DFS 30% vs 74%, logerank P<.0001; 4-year OS, 48% vs 81%; logerank, P<.0001). The prognosis for patients with T2-4N0 or T2-4Nþ disease could not be derived, however, as T4 is a tumor of any size that invades adjacent organs.
The current analysis of US GI Intergroup RTOG 98-11 was performed to determine if TN category of disease has an impact on survival, relapse, or CF. All endpoints showed statistically significant differences among the TN categories of disease, including OS (P<.0001), DFS (P<.0001), LRF (P<.0001), DM Abbreviations: CDDP Z cisplatin; CI Z confidence interval; HR Z hazard ratio; MMC Z mitomycin; TF Z total failures. * P value from the logerank test.
y P value from c 2 test using the Cox proportional hazards model. z Some 5-year estimates might be unstable due to small sample sizes and therefore, too few patients at risk at 5 years.
(PZ.0011), and CF (PZ.01). The best OS, DFS, and LRF outcomes were found in patients with T2N0 and T3N0 disease categories (5-year OS: 82%, 74%, respectively; DFS, 72%, 61%, respectively; LRF, 17%, 18%, respectively), and the poorest outcomes were in patients with T4N0, T3Nþ, and T4Nþ disease (5-year OS: 57%, 57%, and 42%, respectively; DFS, 50%, 38%, and 31%, respectively; and LRF, 37%, 44%, and 60%, respectively). Survival and LRF outcomes for T2Nþ patients were intermediate between T3N0 and T4N0, as found in prior TN category outcome analyses for patients with colon and rectal cancer (17) (18) (19) . CF was lowest in patients with T2N0 and T2Nþ categories (3-year: 11%, 11%, respectively) and highest in those with T4N0, T3Nþ, and T4Nþ category (3-year: 26%, 27%, 24%, respectively).
Outcomes by TN category and treatment: Current series
Outcome analyses by TN category and treatment were performed in the current series. In the CF analyses, there was a trend for a statistically significant differences among the 6 TN categories in the RT plus 5-FU-MMC arm (PZ.066) but not the RT plus 5-FU/ CDDP arm (PZ.11). In the RT plus 5-FU/MMC arm, 3-year CF rates for T2N0 and T2Nþ patients were only 9% and 4%, respectively.
Survival and relapse analyses revealed significant difference in OS, DFS, LRF, and DM among the 6 TN categories on both treatment arms. In the RT plus 5-FU/MMC arm, patients with T3-4Nþ disease were more likely to die than those with T2N0 disease category, but on the RT plus 5-FU/CCDP arm, those with T4N0 category were also more likely to die. With regard to DFS, TN categories of patients more likely to fail on the RT plus 5-FU/MMC arm are T3N0 and T2-4Nþ, whereas on the RT plus 5-FU/CDDP arm those most likely to fail include T4N0 and T2-3Nþ.
Conclusions
The impact of TN category on outcomes for patients treated with CCRT for anal carcinoma are somewhat similar to what has been found in prior analyses of outcomes by TN category for patients with colorectal cancer (17) (18) (19) . In both anal and colorectal cancer patients, those with 2 high risk factors (higher T category, Nþ) have poorer survival and higher relapse rates than those with 1 high risk factor (10, (17) (18) (19) (20) . In the current analysis, patients with T2-3N0 category disease had the best survival and lowest relapse rates, whereas those with T3-4Nþ category disease had the poorest survival rates and highest relapse rates. A subset of patients with involved nodes (T2Nþ) had similar or better prognosis than a node-negative, high T category subset (T4N0). Potential strategies to improve outcomes for patients with anal canal carcinoma include treatment intensification, treatment modification based on positron emission tomography (PET) response, and individualized molecular medicine-based treatment (8, (21) (22) (23) (24) . Treatment intensification and modification has implications with regard to each potential component of treatment (RT, chemotherapy, surgery), but evaluation of such should vary by TN category of disease (21) .
Evaluation of RT intensification and optimization of concurrent chemotherapy during external beam RT are appropriate, especially in patients with high rates of CF and LRF after CCRT (T4N0 and T3-4Nþ in the current analysis). RT intensification may occur as a result of both an increase in RT dose (increase boost dose to 65-70 Gy) and decrease in treatment duration. Both strategies are most feasible with intensity modulated RT, which decreases patient morbidity in both single institution and multi-institution studies, including a phase 2 RTOG trial (25) . Whether the intense concurrent 5-FU regimen of 1000 mg/m 2 on days 1 to 4 and days 29 to 32 of RT could be replaced by rectal cancer regimens remains to be determined.
As local disease control becomes optimized, systemic approaches may need to be re-evaluated for patients with a TN category of disease who have higher risks of systemic relapse (eg, T4N0/T2-4Nþ). Some anal carcinomas express biomarkers of therapy resistance such as sonic hedgehog, nuclear factor kappa B, and nuclear Gli-1 (26) , which lend themselves to therapeutic exploitation.
Earlier surgical salvage may be appropriate in patients with high rates of CF and LRF after CCRT (T4N0, T3-4Nþ). For such patients, it may be preferable to perform a baseline PET-CT study and to repeat PET-CT within 4 to 6 weeks of completion of treatment (23, 24) . Patients with less than optimal PET less than optimal PET response could proceed to early surgical salvage, which might include local excision in select patients. As two-thirds to three-fourths of patients with high-risk TN categories maintained sphincter preservation with CCRT in both the PMH (3) and current series, initial treatment with CCRT is still the most appropriate approach.
